This targeted inhibition of BCL-2 family members has previously been shown to inhibit neuroblastoma tumor growth as both single agents and in combination with standard-of-care therapy (48), although, in the setting of relapsed neuroblastoma, it appears that the ability of these drugs to lower the apoptotic threshold is not sufficient to overcome the JNK impairment of these resistant tumors, which should be noted for the further clinical development of this class of drugs. This evidence concerns the gene BCL2 and neoplasm.